Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: A population-based analysis in the UK

Diabetic Medicine

Volumn 24, Issue 12, 2007, Pages 1412-1418

  Rubino, A ^a   McQuay, L J ^a   Gough, S C ^b   Kvasz, M ^c   Tennis, P ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Analytica International   (United States)

Author keywords

Complications; Delay; Insulin therapy; Oral glucose lowering agents; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG TREATMENT FAILURE; FEMALE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; STROKE; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT FAILURE;

EID: 36549089440     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02279.x     Document Type: Article

References (23)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared to conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
2. Turner RC, Cull CA, Fringhi V, Holman RR for the UKPDS Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. J Am Med Assoc 1999 281 : 2005 2011.
3. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005 28 : 995 1000.
4. McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A et al. Clinical Guidelines and Evidence Review for Type 2 Diabetes: Management of Blood Glucose. Sheffield : ScHARR, University of Sheffield 2001. Available at http://www.nice.org.uk/page.aspx?o=36881 Last accessed 16 January 2007.
5. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006 23 : 579 593.
6. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 1972.
7. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care 2003 9 : 213 217.
8. American Diabetes Association. Standard of medical care for patients with diabetes mellitus: clinical practice recommendations 1999. Diabetes Care 2002 22 : S5 S20.
9. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004 12 : 1 7.
10. Joint Formulary Committee. British National Formulary, 48th edn. London : British Medical Association and Royal Pharmaceutical Society of Great Britain, 2004.
11. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004 27 : 1535 1540.
12. Fox KM, Gerber RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom General Practice Research Database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006 28 : 388 395.
13. UK Prospective Diabetes Study (UKPDS) Group. A 6-year, randomized, controlled trial comparing sulphonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998 128 : 165 175.
14. Diabetes UK. UKPDS - Implications for the Care of People with Type 2 Diabetes. Position statement. Available at http://www.diabetes.org.uk/About_us/ Our_Views/Position_statements/ UKPDS_Implications_for_the_care_of_people_with_Type_2_diabetes_/ Last accessed 16 January 2007.
15. American Diabetes Association. Standard of medical care in diabetes (position statement). Diabetes Care 2004 27 : S15 S35.
16. Kenny C. Diabetes and the quality and outcomes framework. Br Med J 2005 331 : 1097 1098.
17. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002 26 : S18 S24.
18. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patient's fears and hopes about insulin therapy: the basis of patient's reluctance. Diabetes Care 1997 20 : 292 298.
19. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR et al., The International DAWN, Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-sectional Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005 28 : 2673 2679.
20. Hauber AB, Johnson FR, Sauriol L, Lescrauwaet B. Risking health to avoid injections - preferences of Canadians with type 2 diabetes. Diabetes Care 2005 28 : 2243 2245.
21. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS et al JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006 55 : 2401 2411.
22. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract 2006 60 : 1471 1483.
23. Audige L, Hanson B, Kopjar B. Issues in the planning and conduct of non-randomised studies. Injury 2006 37 : 340 348.